glycan and disease n.
Skip this Video
Loading SlideShow in 5 Seconds..
Glycan and disease PowerPoint Presentation
Download Presentation
Glycan and disease

Loading in 2 Seconds...

play fullscreen
1 / 16

Glycan and disease - PowerPoint PPT Presentation

  • Uploaded on

Glycan and disease. Classification of human diseases known to be related to glycans. Infectious disease Bacterial and viral infection Parasite infection Genetic disorders Glycan synthesis/degradation related Glycosylation related Acquired diseases Cancer.

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

Glycan and disease

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
    Presentation Transcript
    1. Glycan and disease

    2. Classification of human diseases known to be related to glycans • Infectious disease • Bacterial and viral infection • Parasite infection • Genetic disorders • Glycan synthesis/degradation related • Glycosylation related • Acquired diseases • Cancer

    3. Polysaccharides on bacterial surface • Polysaccharide capsule • Covers bacterial surface • Targets of immune clearance • Human’s ability to generate antibody responses against bacteria diminished at extremes of age • Certain bacteria avoid antibody defenses through molecular mimicry of common host glycan structure • group A Streptococcus (GAS): capsule of hyaluronan, identical to the nonsulfatedglycosaminoglycan • Neisseriameningitidis: homopolymericsialic acid capsules • Certain pathogens has the great diversity of capsular structures • Can be used to classify different “serotype” strains • Individuals can be repeatedly infected over their lifetime by different serotype strains of the same bacterial pathogen • Genetic exchange of capsule biosynthetic genes among serotype strains of a specific species (e.g., the polysialyltransferase gene in meningococcus) can lead to capsule switching in vivo

    4. Glycan adhesins and receptors • Most microorganisms express more than one type of adhesins (mainly lectins) • mediated through terminal sugars or internal motifs.

    5. Polymicrobial biofilm • Biofilm formation is a mechanism that promotes bacterial attachment to host surfaces; • Bacteria within biofilms communicate with one another through soluble signaling molecules in a process known as “quorum sensing” to optimize gene expression for survival; • In biofilms, bacteria live under nutrient limitation and in a dormant state in which defense molecules (e.g., antimicrobial peptides) produced by the immune system and pharmacologic antibiotics are less effective; • The excellularpolysaccahride (EPS) matrix can bind and inactivate the defense molecules, contributing to the persistence of the biofilm and difficulty in medical treatment of biofilm infections.

    6. Polymicrobial biofilm (dental plaque)

    7. Bacterial toxins binding to glycans and entering the host cell

    8. Mechanism of virus entering the cell

    9. Viral infection: glycan-GBP interaction

    10. Glycan-GBP binding in parasite infection

    11. Defects in glycoprotein degradation (in lysosomes)

    12. Defects in glycosaminoglycan degradation—the mucopolysaccharidoses

    13. Defects in glycolipid degradation

    14. Therapies of lysosomal enzyme deficiency • Enzyme replacement therapy (ERT) • Injection of defective enzymes • Enzyme enhancement therapy (EET) • The inhibitors of the enzymes behave as molecular chaperones to stabilize the mutated enzymes in the endoplasmic reticulum to prevent their misfolding and proteasomal degradation • Even though SRT seems promising, the expected benefits to date have been minimal. • Substrate reduction therapy (SRT) • Reducing a glycan’s synthetic rate by can offset the effects of low glycosidase activity

    15. Genetic disorder of glycosylations • Inherited disorders occurred in all major glycan synthesis • N-glycan assembly: congenital disorders of glycosylation (CDG) • Galactose metabolism: Galactosemia • Synthesis of the core region of xylose-based GAG chains: Ehlers–Danlos Syndrome • Defects in the formation of heparan sulfate (HS): hereditary multiple exostosis

    16. Altered glycosylation in cancer • Increased β1-6GlcNAc branching of N-glycans; • Changes in the amount, linkage, and acetylation of sialic acids; • Truncation of O-glycans, leading to expression of Tn and sialylTn antigens; • Expression of the nonhuman sialic acid N-glycolylneuraminic acid, likely incorporated from dietary sources; • Expression of sialylated Lewis structures and selectin ligands; • Altered expression and enhanced shedding of glycosphingolipids; • Increased expression of galectins and poly-N-acetyllactosamines; • Altered expression of ABH(O) blood-group-related structures; • Alterations in sulfation of glycosaminoglycans; • Increased expression of hyaluronan • Loss of expression of GPI lipid anchors.